Doxycycline as a potential partner of COVID-19 therapies

Alexandre E. Malek; Bruno P. Granwehr; Dimitrios P. Kontoyiannis

doi:10.1016/j.idcr.2020.e00864

Doxycycline as a potential partner of COVID-19 therapies

Alexandre E. Malek, Bruno P. Granwehr, Dimitrios P. Kontoyiannis

Infectious Diseases, Infection Control, and Employee Health

Research output: Contribution to journal › Editorial › peer-review

73 Scopus citations

Abstract

Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a long time. Therefore, the repurposing of existing drugs for new indications is needed. In this article, we argue for the potential benefits of using doxycycline with either hydroxycholoroquine or other putative agents for COVID-19 treatment, as doxycycline has antiviral and anti-inflammatory activities by dampening the cytokine storm and to prevent lung damage.

Original language	English (US)
Article number	e00864
Journal	IDCases
Volume	21
DOIs	https://doi.org/10.1016/j.idcr.2020.e00864
State	Published - 2020

Keywords

2019 novel coronavirus
COVID-19
Doxycycline
Hydroxychloroquine
Remdesivir

ASJC Scopus subject areas

Infectious Diseases

Access to Document

10.1016/j.idcr.2020.e00864

Cite this

@article{8618277f649b40d3b2997de72b539a6a,

title = "Doxycycline as a potential partner of COVID-19 therapies",

abstract = "Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a long time. Therefore, the repurposing of existing drugs for new indications is needed. In this article, we argue for the potential benefits of using doxycycline with either hydroxycholoroquine or other putative agents for COVID-19 treatment, as doxycycline has antiviral and anti-inflammatory activities by dampening the cytokine storm and to prevent lung damage.",

keywords = "2019 novel coronavirus, COVID-19, Doxycycline, Hydroxychloroquine, Remdesivir",

author = "Malek, {Alexandre E.} and Granwehr, {Bruno P.} and Kontoyiannis, {Dimitrios P.}",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2020",

doi = "10.1016/j.idcr.2020.e00864",

language = "English (US)",

volume = "21",

journal = "IDCases",

issn = "2214-2509",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Doxycycline as a potential partner of COVID-19 therapies

AU - Malek, Alexandre E.

AU - Granwehr, Bruno P.

AU - Kontoyiannis, Dimitrios P.

PY - 2020

Y1 - 2020

N2 - Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a long time. Therefore, the repurposing of existing drugs for new indications is needed. In this article, we argue for the potential benefits of using doxycycline with either hydroxycholoroquine or other putative agents for COVID-19 treatment, as doxycycline has antiviral and anti-inflammatory activities by dampening the cytokine storm and to prevent lung damage.

AB - Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a long time. Therefore, the repurposing of existing drugs for new indications is needed. In this article, we argue for the potential benefits of using doxycycline with either hydroxycholoroquine or other putative agents for COVID-19 treatment, as doxycycline has antiviral and anti-inflammatory activities by dampening the cytokine storm and to prevent lung damage.

KW - 2019 novel coronavirus

KW - COVID-19

KW - Doxycycline

KW - Hydroxychloroquine

KW - Remdesivir

UR - http://www.scopus.com/inward/record.url?scp=85086173572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086173572&partnerID=8YFLogxK

U2 - 10.1016/j.idcr.2020.e00864

DO - 10.1016/j.idcr.2020.e00864

M3 - Editorial

C2 - 32566483

AN - SCOPUS:85086173572

SN - 2214-2509

VL - 21

JO - IDCases

JF - IDCases

M1 - e00864

ER -

Doxycycline as a potential partner of COVID-19 therapies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this